Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the benefit of sorafenib in patients with a rising
PSA after treatment with radiation therapy or surgery who are NOT receiving with androgen
ablation therapy.